{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:21:29Z","timestamp":1739424089080,"version":"3.37.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T16:10:48Z","timestamp":1728144648000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Local Control With Palliative Radiotherapy for Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Robert W.","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph F.","family":"Fleuranvil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-4732","authenticated-orcid":false,"given":"Randa","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-4565","authenticated-orcid":false,"given":"Sydney D.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-1504","authenticated-orcid":false,"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-9811","authenticated-orcid":false,"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Jemal A Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.10.004_bib0002","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. Surveillance, Epidemiology, and End Results Program. URL:https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"7","key":"10.1016\/j.clml.2024.10.004_bib0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas \u2013 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10040","key":"10.1016\/j.clml.2024.10.004_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(16)30954-0","article-title":"Multiple myeloma\u2014translation of trial results into reality","volume":"388","author":"Moreau","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clml.2024.10.004_bib0005","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2024.10.004_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.clml.2024.10.004_bib0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood.V128.22.193.193","article-title":"Correlation between somatic mutation burden, neoantigen load and progression free survival in multiple myeloma: analysis of MMRF CoMMpass study","volume":"128","author":"Miller","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.10.004_bib0008","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.004_bib0009","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.adro.2022.101016","article-title":"Radiation therapy for relapsed or refractory diffuse large B-cell lymphoma: what is the right regimen for palliation?","volume":"7","author":"Wright","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.prro.2019.09.013","article-title":"Impact of double- or triple-hit pathology on rates and durability of radiation therapy response among patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Kim","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.004_bib0011","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.ijrobp.2023.06.068","article-title":"Phase II multi-institutional study of a low-dose (4 Gy) palliative response-adapted radiotherapy regimen for symptomatic bone metastases from multiple myeloma: planned interim analysis of first 40 patients","volume":"117","author":"Ballas","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.10.004_bib0012","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00066-017-1154-5","article-title":"Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma","volume":"193","author":"Rudzianskiene","year":"2017","journal-title":"Strahlentherapie und Onkol"},{"issue":"5","key":"10.1016\/j.clml.2024.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ijrobp.2005.10.018","article-title":"Short-course radiotherapy is not optimal for spinal cord compression due to myeloma","volume":"64","author":"Rades","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.clml.2024.10.004_bib0014","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.3324\/haematol.2019.235804","article-title":"New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity","volume":"105","author":"Elhammali","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.10.004_bib0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqad108","article-title":"Superior detection rate of plasma cell FISH using FACS-FISH","volume":"161","author":"Gagnon","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.clml.2024.10.004_bib0017","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2024.10.004_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.10.004_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0167-8140(99)00110-3","article-title":"The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study","volume":"52","author":"Steenland","year":"1999","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.10.004_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Harstell","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.clml.2024.10.004_bib0022","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Sze WM Palliative radiotherapy trials for bone metastases: a systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.10.004_bib0023","article-title":"Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)","volume":"75:54-63","author":"Roos","year":"2005","journal-title":"Radiother Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.10.004_bib0024","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"Multiple myeloma, version 3.2022: featured updates to the NCCN guidelines. JNCCN","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"22","key":"10.1016\/j.clml.2024.10.004_bib0026","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.2023021187","article-title":"Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas","volume":"142","author":"Yadav","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.004_bib0027","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:19Z","timestamp":1739364439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024023632"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Local Control With Palliative Radiotherapy for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}